Arcutis Biotherapeutics Inc (ARQT) Stock Price, Quote & News

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 418 5006

Website: www.arcutis.com

Address:

3027 Townsgate Road, Suite 300, Westlake Village, United States

5StarTrader Apr. 23 at 1:59 PM

$ARQT I’m expecting a gap higher on Q1 EPS and new share price highs, before the buyout and the mega gap higher takes place.

1 · Reply

NJgolfer Apr. 22 at 2:40 PM

$ARQT down into $19.X area where there are multiple Fibonacci retrace ment levels, long term EMA, and a prior volume shelf. Will be stalking at that price point 👉

1 · Reply

DARKP00L Apr. 22 at 12:15 PM

$ARQT 08:10 on Apr. 22 2026 Arcutis Biotherapeutics Announces ZORYVE Cream Receives Strong Recommendation, With High Certainty Of Clinical Evidence, In AAD Clinical Practice Guidelines For Management Of Pediatric Atopic Dermatitis #tradeideas

0 · Reply

Rhody27 Apr. 21 at 4:12 PM

$ARQT adding again.

0 · Reply

jdlman Apr. 21 at 3:33 PM

$ACHR $ARQT $DUOT .... if i had a little extra cash , i wonder which one i would go for , while they are all speculative, ifeel one of these will sky rocket in a year

0 · Reply

Dr_Stoxx Apr. 21 at 2:25 PM

$ARQT perfect 5-step short signal here.

0 · Reply

Bornjever Apr. 17 at 3:33 PM

$ARQT so projected sales of our psoriasis cream and foam is at least 1.50 billion plus 500 million for other drugs so we are doubling our sales force to get the news out to the world about efficacy and convenience of foam for hairy areas and cream for rest as we are at 500 million but need to push our better meds out to doctors and clinics and hospitals and am convinced we will see amazing results as shorts have had run over most smaller bio as they steal retail shares because they put stop loss and they know where. Laws should show shorts the way buyers are shown!!! VERY

0 · Reply

SuperGreenToday Apr. 16 at 7:05 AM

$ARQT Share Price: $24.56 Contract Selected: Sep 18, 2026 $25 Calls Buy Zone: $4.90 – $6.05 Target Zone: $8.13 – $9.94 Potential Upside: 57% ROI Time to Expiration: 154 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Luise01128 Apr. 15 at 7:38 PM

$ARQT

0 · Reply

kareem1988 Apr. 14 at 9:26 AM

Biotech had a strong session yesterday with some solid movers. Kodiak Sciences $KOD hit a new 52-week high, while Biohaven $BHVN jumped on a fresh analyst upgrade. Alpha Tau Medical $DRTS also stayed hot, closing up over 7%. Arcutis Biotherapeutics $ARQT rounded out the green day as its commercial momentum continues to pick up steam. Interesting to see these names showing relative strength while the rest of the market feels shaky

3 · Reply

Arcutis' ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

Apr 15, 2026, 4:00 PM EDT - 9 days ago

Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

Apr 14, 2026, 11:00 AM EDT - 11 days ago

Arcutis Biotherapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Mar 31, 2026, 4:00 PM EDT - 24 days ago

Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference

Mar 28, 2026, 11:00 AM EDT - 4 weeks ago

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

Mar 18, 2026, 8:00 AM EDT - 5 weeks ago

Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting

Mar 10, 2026, 9:00 AM EDT - 6 weeks ago

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology

Mar 5, 2026, 9:00 AM EST - 7 weeks ago

Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth

Mar 3, 2026, 8:00 AM EST - 7 weeks ago

Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis

Mar 2, 2026, 1:50 PM EST - 7 weeks ago

Arcutis Biotherapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 27, 2026, 4:00 PM EST - 2 months ago

Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference

Feb 25, 2026, 4:30 PM EST - 2 months ago

Arcutis Biotherapeutics Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:00 PM EST - 2 months ago

Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 24, 2026, 9:15 AM EST - 2 months ago

Professional Golfer Max Homa Joins Arcutis' Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments

Feb 11, 2026, 11:30 AM EST - 2 months ago

Arcutis Biotherapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 4:00 PM EST - 2 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 2, 2026, 8:00 AM EST - 2 months ago

Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis

Jan 26, 2026, 8:00 AM EST - 3 months ago

Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa

Jan 22, 2026, 4:00 PM EST - 3 months ago

Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference

Jan 21, 2026, 8:00 AM EST - 3 months ago

Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions

Jan 12, 2026, 8:00 AM EST - 3 months ago

Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones

Dec 8, 2025, 4:00 PM EST - 4 months ago

Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

Nov 17, 2025, 8:00 AM EST - 5 months ago

FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

Nov 13, 2025, 8:00 AM EST - 5 months ago

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

Nov 11, 2025, 8:30 AM EST - 5 months ago

Arcutis Biotherapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 4, 2025, 8:00 AM EST - 6 months ago

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology

Oct 30, 2025, 9:15 AM EDT - 6 months ago

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments

Oct 30, 2025, 8:00 AM EDT - 6 months ago

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

Oct 28, 2025, 10:30 AM EDT - 6 months ago

Arcutis Biotherapeutics Transcript: Q3 & Investor Day 2025

Oct 28, 2025, 8:30 AM EDT - 6 months ago

Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results

Oct 27, 2025, 4:00 PM EDT - 6 months ago

Arcutis to Present at Upcoming Investor Conferences

Oct 24, 2025, 8:00 AM EDT - 6 months ago

Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference

Oct 6, 2025, 8:00 AM EDT - 7 months ago

FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

Sep 29, 2025, 4:00 PM EDT - 7 months ago

Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025

Sep 17, 2025, 4:00 AM EDT - 7 months ago

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

Sep 16, 2025, 9:00 AM EDT - 7 months ago

Allure Magazine Honors Arcutis' ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award

Sep 10, 2025, 10:30 AM EDT - 8 months ago

Arcutis Biotherapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 2:35 PM EDT - 8 months ago

Arcutis Biotherapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 11:43 AM EDT - 8 months ago

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

Sep 3, 2025, 9:45 AM EDT - 8 months ago

Arcutis Biotherapeutics Transcript: Citi's Biopharma Back to School Conference

Aug 6, 2025, 4:30 PM EDT - 9 months ago

Arcutis Biotherapeutics Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 9 months ago

Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update

Jul 23, 2025, 4:00 PM EDT - 9 months ago

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

Jun 26, 2025, 8:00 AM EDT - 10 months ago

Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

Jun 10, 2025, 4:00 PM EDT - 11 months ago

Arcutis Biotherapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 10, 2025, 8:00 AM EDT - 11 months ago

Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

Jun 6, 2025, 8:00 AM EDT - 11 months ago

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

May 29, 2025, 4:00 PM EDT - 11 months ago

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

May 22, 2025, 2:12 PM EDT - 1 year ago

Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

May 15, 2025, 9:29 AM EDT - 1 year ago

New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice

May 7, 2025, 11:18 AM EDT - 1 year ago

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

May 6, 2025, 4:30 PM EDT - 1 year ago

Arcutis Biotherapeutics Earnings Call Transcript: Q1 2025

May 6, 2025, 4:00 PM EDT - 1 year ago

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

Apr 10, 2025, 4:30 PM EDT - 1 year ago

Arcutis Announces Chief Financial Officer Transition

Apr 8, 2025, 11:00 AM EDT - 1 year ago

Arcutis Biotherapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 1:16 PM EDT - 1 year ago

Arcutis and Padagis Agree to Stay Patent Lawsuit

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 8:16 AM EDT - 1 year ago

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

TNXP

Mar 7, 2025, 8:00 AM EST - 1 year ago

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

Mar 4, 2025, 9:50 AM EST - 1 year ago

Arcutis Biotherapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 28, 2025, 9:00 AM EST - 1 year ago

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

Feb 26, 2025, 8:00 AM EST - 1 year ago

U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Feb 25, 2025, 4:30 PM EST - 1 year ago

Arcutis Biotherapeutics Earnings Call Transcript: Q4 2024

Feb 25, 2025, 4:00 PM EST - 1 year ago

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 6, 2025, 1:00 PM EST - 1 year ago

Arcutis Biotherapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Nov 6, 2024, 4:30 PM EST - 1 year ago

Arcutis Biotherapeutics Earnings Call Transcript: Q3 2024

Sep 5, 2024, 1:50 PM EDT - 1 year ago

Arcutis Biotherapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Arcutis Biotherapeutics Earnings Call Transcript: Q2 2024

Jul 29, 2024, 8:30 AM EDT - 1 year ago

Arcutis Biotherapeutics Transcript: FDA Announcement

Jun 12, 2024, 1:20 PM EDT - 2 years ago

Arcutis Biotherapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

May 14, 2024, 4:30 PM EDT - 2 years ago

Arcutis Biotherapeutics Earnings Call Transcript: Q1 2024

Apr 11, 2024, 2:15 PM EDT - 2 years ago

Arcutis Biotherapeutics Transcript: 23rd Annual Needham Virtual Healthcare Conference

Mar 4, 2024, 2:10 PM EST - 2 years ago

Arcutis Biotherapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 27, 2024, 8:30 AM EST - 2 years ago

Arcutis Biotherapeutics Earnings Call Transcript: Q4 2023

Feb 7, 2024, 10:00 AM EST - 2 years ago

Arcutis Biotherapeutics Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 22, 2024, 4:30 PM EST - 2 years ago

Arcutis Biotherapeutics Transcript: Launch Call

Dec 18, 2023, 8:30 AM EST - 2 years ago

Arcutis Biotherapeutics Transcript: FDA Announcement

Nov 3, 2023, 8:30 AM EDT - 2 years ago

Arcutis Biotherapeutics Earnings Call Transcript: Q3 2023

Sep 19, 2023, 8:30 AM EDT - 2 years ago

Arcutis Biotherapeutics Transcript: Study Result

Sep 12, 2023, 2:55 PM EDT - 2 years ago

Arcutis Biotherapeutics Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Aug 8, 2023, 4:30 PM EDT - 2 years ago

Arcutis Biotherapeutics Earnings Call Transcript: Q2 2023

May 9, 2023, 4:30 PM EDT - 3 years ago

Arcutis Biotherapeutics Earnings Call Transcript: Q1 2023

Feb 28, 2023, 4:30 PM EST - 3 years ago

Arcutis Biotherapeutics Earnings Call Transcript: Q4 2022

Dec 12, 2022, 8:30 AM EST - 3 years ago

Arcutis Biotherapeutics Transcript: Study Result

Nov 8, 2022, 5:00 PM EST - 3 years ago

Arcutis Biotherapeutics Earnings Call Transcript: Q3 2022

Aug 1, 2022, 8:30 AM EDT - 4 years ago

Arcutis Biotherapeutics Transcript: FDA Announcement

Jun 6, 2022, 8:30 AM EDT - 4 years ago

Arcutis Biotherapeutics Transcript: Study Result

Mar 28, 2022, 10:30 AM EDT - 4 years ago

Arcutis Biotherapeutics Transcript: Investor Day 2022

5StarTrader Apr. 23 at 1:59 PM

$ARQT I’m expecting a gap higher on Q1 EPS and new share price highs, before the buyout and the mega gap higher takes place.

1 · Reply

NJgolfer Apr. 22 at 2:40 PM

$ARQT down into $19.X area where there are multiple Fibonacci retrace ment levels, long term EMA, and a prior volume shelf. Will be stalking at that price point 👉

1 · Reply

DARKP00L Apr. 22 at 12:15 PM

0 · Reply

Rhody27 Apr. 21 at 4:12 PM

$ARQT adding again.

0 · Reply

jdlman Apr. 21 at 3:33 PM

$ACHR $ARQT $DUOT .... if i had a little extra cash , i wonder which one i would go for , while they are all speculative, ifeel one of these will sky rocket in a year

0 · Reply

Dr_Stoxx Apr. 21 at 2:25 PM

$ARQT perfect 5-step short signal here.

0 · Reply

Bornjever Apr. 17 at 3:33 PM

0 · Reply

SuperGreenToday Apr. 16 at 7:05 AM

0 · Reply

Luise01128 Apr. 15 at 7:38 PM

$ARQT

0 · Reply

kareem1988 Apr. 14 at 9:26 AM

3 · Reply

MoonlitCocoa Apr. 10 at 12:21 PM

$ARQT need volume

0 · Reply

Luise01128 Apr. 9 at 7:05 PM

$ARQT

0 · Reply

Bornjever Apr. 9 at 1:57 PM

$ARQT our ZORYVE cream will eventually sell one billion worth and our foam will sell 500 million and then we have dermatitis and other products so the market keeps dragging this company down but the numbers will bear out the truth that if we investors keep denying the increasing revenue then ideal time for 40 dollar per share buyout to take place very soon. VERY

0 · Reply

OfficialStocktwitsUser Apr. 1 at 8:37 PM

$ARQT RSI: 57.52, MACD: -0.7164 Vol: 1.02, MA20: 22.96, MA50: 24.94 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Rhody27 Mar. 31 at 6:57 PM

$ARQT excellent

0 · Reply

Damian23 Mar. 31 at 3:45 PM

$ARQT About time this dog moves a little bit after -33% decline.

0 · Reply

DonCorleone77 Mar. 29 at 3:38 PM

$ARQT Arcutis Biotherapeutics presents new Phase 2 results on Zoryve cream Arcutis Biotherapeutics announced new data from the Integument-Infant Phase 2 trial demonstrating that Zoryve cream 0.05% reduced signs and symptoms of atopic dermatitis, the most common form of eczema, in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis. These results build upon the topline results announced last month and further support the potential of investigational Zoryve cream as a treatment option for this youngest and very vulnerable population. The results were presented today during a late-breaking podium presentation at the 2026 American Academy of Dermatology, AAD, Annual Meeting in Denver, CO.

0 · Reply

Bornjever Mar. 28 at 10:08 PM

$ARQT well once again the folks are giving us shorts and FUD are giving us folks that know this company with one of the most effective meds in the world and it is ZORYVE for psoriasis and I would not be here but this will go to 40 with sales and profits or buyout

0 · Reply

AlertsAndNews Mar. 28 at 4:57 PM

$ARQT Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting "Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT program ZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four weeks Caregivers reported rapid improvement in itch in as little as 10 minutes in nearly half of infants Results from additional studies across the ZORYVE portfolio being presented in three poster presentations"

1 · Reply

Franciscomaligno Mar. 28 at 3:13 PM

$ARQT first of all, it's not just arqt but all biotech index. I hold 4 biotech stocks, all red of 35/45% , while this is "only" - 20%. Anyway to reach 15$, this should loose 30% not 10%. IMPOSSIBLE!!!

1 · Reply

Damian23 Mar. 27 at 6:35 PM

$ARQT 32% from highs, never good , if the index drop another 10% it could get into 15$..... It sucks giving away most of the gains but it is what it is, holding the 50 Fibo retracement now

0 · Reply

CaptainBullish764 Mar. 27 at 12:35 PM

$RCKT reminds me of $ARQT let’s see the same run!

0 · Reply

Market Cap	2.86B
Revenue (ttm)	376.07M
Net Income (ttm)	-16.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	74.22
Profit Margin	-4.29%
Debt to Equity Ratio	0.58

Volume	1,090,100
Avg Vol	1,311,374
Day's Range	N/A - N/A
Shares Out	125.07M
Stochastic %K	27%
Beta	1.76
Analysts	Strong Sell
Price Target	$34.75